Kintara director Keith Murphy resigns from board effective Feb 4, 2022

TuHURA Biosciences, Inc./NV

Keith Murphy resigned from the Board of Directors, Compensation Committee, and Nominating and Corporate Governance Committee, effective February 4, 2022.
Resignation was not due to any disagreements with the company regarding its operations, policies, or practices.
No replacement for Murphy on the board or committees has been announced in this filing.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Keith Murphy

Director

HURA · TuHURA Biosciences, Inc./NV

Effective: 2022-02-04
Filed: February 8, 2022, 6:59 PM ET

On February 4, 2022, Keith Murphy submitted his resignation from the Board of Directors (the “Board”) of Kintara Therapeutics, Inc. (the “Company”), effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Keith Murphy resigned as Director at TuHURA Biosciences, Inc./NV.

Action: resigned
Role: Director

Exact text from the filing

On February 4, 2022, Keith Murphy submitted his resignation from the Board of Directors (the “Board”) of Kintara Therapeutics, Inc. (the “Company”), effective immediately.

View on SEC.gov

TuHURA Biosciences, Inc./NV filing history →

Source: SEC EDGAR

accession 0001564590-22-004233

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.